The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin stabilizers for transthyretin amyloid cardiomyopathy.
Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy Read More »
The approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin stabilizers for transthyretin amyloid cardiomyopathy.
FDA Approves First RNAi Silencer for Rare Type of Cardiomyopathy Read More »
A former HHS secretary argues healthcare should be able to utilize skilled immigrant clinicians to stem the effects of labor shortages.
The future of US healthcare depends on smarter immigration policies Read More »
The health IT vendor hasn’t filed quarterly or annual reports since November 2022. Veradigm was delisted from Nasdaq for failing to comply with financial reporting requirements last year.
Veradigm releases long-awaited financial results Read More »
The deal, which removes Cigna from the volatile Medicare Advantage market, closed a little over a year after being announced.
Cigna closes $3.7B sale of Medicare business to HCSC Read More »
Cherodeep Goswami will begin his new role as Providence’s chief information and digital officer on May 12.
Providence names new chief information and digital officer Read More »
GE Healthcare, Synchron and robotics companies were among the medtech firms that used Nvidia’s GTC 2025 conference to share updates on their work with the AI computing leader.
Quest, Google team on gen AI; GE Healthcare plans autonomous imaging Read More »
Businesses that previously found pursuing USMCA treatment cost-prohibitive are scrambling to determine if they meet the trade deal’s requirements.
Tariffs are paused for USMCA-compliant goods. How can companies qualify? Read More »
Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.
Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M Read More »
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can achieve deep B cell depletion, giving it the potential to reset the immune system.
Sanofi Commits $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease Read More »
